医学
托珠单抗
复视
格雷夫斯病
不利影响
回顾性队列研究
眼病
外科
甲状腺
内科学
疾病
作者
Rubén Pampín Sánchez,Cristina Martínez-Mugica-Barbosa,E. Fonseca-Aizpuru,Francisco Javier Barbazán-Vázquez,Beatriz Fernández-González,Loreto Buznego-Súárez
标识
DOI:10.1016/j.medcli.2022.05.007
摘要
Thyroid eye disease (TED) is a complex and incompletely understood rare autoimmune disorder.To analyze the experience and the outcomes obtained with the use of intravenous tocilizumab in the treatment of TED.A retrospective analysis of adult patients diagnosed with active TED resistant to intravenous corticosteroids treated in a tertiary hospital between May 2012 and May 2021.Eleven patients were included with a mean age of 52±12 (range 35-67) years. Nine patients were female and two were male. Patients received a median of 5±3.2 doses. Twenty out of twenty-four eyes achieved inactivation of TED at week 16. Proptosis response was achieved in 6/8 patients and diplopia response in 3/8 patients. The GO-QOL questionnaire showed clinically significant improvement in 9/11 patients. No serious adverse effects were reported during tocilizumab treatment. One patient required decompressive surgery 15 months after tocilizumab therapy.The results obtained show that the use of tocilizumab in the treatment of this pathology can be a good alternative.
科研通智能强力驱动
Strongly Powered by AbleSci AI